This novel finding supports the notion that SOST acts as oncogenic factor to promote breast cancer bone metastasis [13, 14] and suggests that SOST may be a therapeutic target for inhibiting breast cancer bone metastasis. The gene discussed is SOST; the disease is breast carcinoma.